GI
Grifols, S.A.
GIKLY · OTC
$5.78 +0.52% (+$0.03)
1M -0.52%
Market Cap 13.1B €
P/E Ratio 28.87x
Div. Yield 0.82%
ROE 8.43%
Bulios Fair Price
$3.8
34.3% downside
Current Price
$5.78
Undervalued Fair Value Overvalued
According to Bulios Fair Price, GIKLY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
66 /100
Fair P/E 28.87x
EV/EBITDA 13.01x
P/S 1.76x
Growth
64 /100
Stable EPS growth 20.51%
Rev. growth 7.46%
Book val. growth 4.92%
Profitability
64 /100
Moderate Gross margin 37.23%
Net margin 6.09%
Op. margin 16.66%
Quality
31 /100
Poor ROIC 5.48%
ROE 8.43%
ROA 2.25%
Debt
35 /100
Moderate Debt/Equity 1.54x
Current ratio 2.37x
Int. coverage 2.86x
Stability
61 /100
Moderate Beta 1.19x
Rev. volatility 2.76%
EPS volatility 132.48%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about GIKLY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jose Ignacio Abia Buenache
Employees
25,258
Headquarters
Barcelona
Upcoming events
10 NOV
Earnings
Upcoming earnings report